Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anja Seckinger

Showing results (101-110 of 122) with videos related to

Pageof 13
Sort By:
Blood Cancer Journal|January 31, 2019
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patientsKatharina Kriegsmann, Marc-Andrea Baertsch, Mohamed H S Awwad, et al.
Haematologica|August 20, 2016
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
Cancer Immunology Research|July 16, 2020
CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti-PD-L1 TreatmentValentina Volpin, Tillmann Michels, Antonio Sorrentino, et al.
Blood|January 28, 2009
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myelomaDirk Hose, Thierry Rème, Tobias Meissner, et al.
Haematologica|April 5, 2015
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
International Journal of Molecular Sciences|June 27, 2024
Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income CountriesAnja Seckinger, Hans Salwender, Hans Martin, et al.
Leukemia|May 25, 2021
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III TrialHans Salwender, Ahmet Elmaagacli, Maximilian Merz, et al.
Journal of Hematology & Oncology|December 13, 2023
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancersAnja Seckinger, Sara Majocchi, Valéry Moine, et al.
Hematology (Amsterdam, Netherlands)|February 26, 2024
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trialHans Salwender, Niels Weinhold, Axel Benner, et al.
Journal of Hematology & Oncology|December 19, 2024
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myelomaDirk Hose, Seemun Ray, Sina Rößler, et al.
Pageof 13

Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
Blood Cancer Journal|January 31, 2019
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patientsKatharina Kriegsmann, Marc-Andrea Baertsch, Mohamed H S Awwad, et al.
Haematologica|August 20, 2016
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
Cancer Immunology Research|July 16, 2020
CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti-PD-L1 TreatmentValentina Volpin, Tillmann Michels, Antonio Sorrentino, et al.
Blood|January 28, 2009
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myelomaDirk Hose, Thierry Rème, Tobias Meissner, et al.
Haematologica|April 5, 2015
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
International Journal of Molecular Sciences|June 27, 2024
Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income CountriesAnja Seckinger, Hans Salwender, Hans Martin, et al.
Leukemia|May 25, 2021
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III TrialHans Salwender, Ahmet Elmaagacli, Maximilian Merz, et al.
Journal of Hematology & Oncology|December 13, 2023
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancersAnja Seckinger, Sara Majocchi, Valéry Moine, et al.
Hematology (Amsterdam, Netherlands)|February 26, 2024
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trialHans Salwender, Niels Weinhold, Axel Benner, et al.
Journal of Hematology & Oncology|December 19, 2024
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myelomaDirk Hose, Seemun Ray, Sina Rößler, et al.
Pageof 13